Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world safety and efficacy of aponermin and daratumumab-based regimens in patients with multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

BFBaijun FangPZPing ZhangJLJuan Li

Discussion

Loading...

Member takes

Overview

Observational analysis shows 78.57% overall response rate in multiple myeloma patients treated with aponermin and daratumumab, highlighting safety and efficacy benefits.

Key Points

  • Overall response rate was 78.57% with complete response in 14.29% of patients.
  • Patients experienced manageable adverse events, primarily mild hematologic toxicities.
  • Retrospective analysis across 14 multiple myeloma patients treated with aponermin and daratumumab.
  • Findings may enable new treatment approaches for heavily pretreated multiple myeloma patients.

Cite This Study

Fang et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e08dhttps://doi.org/10.1182/blood-2025-7580
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study2025
  2. 2Safety and efficacy of aponermin-based chemotherapy as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma2025
  3. 3Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study2025
  4. 4Aponermin-based regimen as bridging therapy prior to CAR-T cell therapy for relapsed/refractory multiple myeloma2025
  5. 5Daratumumab‐Based Combinational Therapy as Second‐Line Treatment of Relapsed‐Refractory Multiple Myeloma: A Single‐Center Experience2025